Extract
Skeletal muscle weakness is a distinct extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD), which is associated with a poor prognosis [1] and may represent a novel therapeutic target [2]. However, there are only sparse longitudinal data from prospective studies on skeletal muscle weakness and its relationship with disease progression in COPD. Previous studies have been cross-sectional in nature, and have failed to correlate data with baseline measures of exercise performance or systemic inflammation.
Abstract
The short physical performance battery may be a useful endpoint in assessing impact on skeletal muscle dysfunction http://ow.ly/xf8z30dOFMz
Footnotes
This study is registered at ClinicalTrials.gov with identifier number NCT01471587.
Support statement: This study was sponsored by the Royal Brompton & Harefield NHS Foundation Trust and funded by a grant from Innovate UK (1101_CRD_MED_IBD_61188) with contribution in kind from GlaxoSmithKline (GSK), a consortium partner. The follow-up study was funded by Novartis and the entire project was supported by the NIHR Respiratory Biomedical Research Unit at the Royal Brompton & Harefield NHS Foundation Trust and Imperial College, which part-fund Michael I. Polkey's salary. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received January 31, 2017.
- Accepted May 4, 2017.
- Copyright ©ERS 2017